• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物依赖的苯乙酰谷氨酰胺与心血管疾病:现有知识和新见解。

Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights.

机构信息

Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, 430030, China.

出版信息

Front Med. 2024 Feb;18(1):31-45. doi: 10.1007/s11684-024-1055-9. Epub 2024 Mar 1.

DOI:10.1007/s11684-024-1055-9
PMID:38424375
Abstract

Phenylacetylglutamine (PAGln) is an amino acid derivate that comes from the amino acid phenylalanine. There are increasing studies showing that the level of PAGln is associated with the risk of different cardiovascular diseases. In this review, we discussed the metabolic pathway of PAGln production and the quantitative measurement methods of PAGln. We summarized the epidemiological evidence to show the role of PAGln in diagnostic and prognostic value in several cardiovascular diseases, such as heart failure, coronary heart disease/atherosclerosis, and cardiac arrhythmia. The underlying mechanism of PAGln is now considered to be related to the thrombotic potential of platelets via adrenergic receptors. Besides, other possible mechanisms such as inflammatory response and oxidative stress could also be induced by PAGln. Moreover, since PAGln is produced across different organs including the intestine, liver, and kidney, the cross-talk among multiple organs focused on the function of this uremic toxic metabolite. Finally, the prognostic value of PAGln compared to the classical biomarker was discussed and we also highlighted important gaps in knowledge and areas requiring future investigation of PAGln in cardiovascular diseases.

摘要

苯乙酰谷氨酰胺(PAGln)是一种氨基酸衍生物,来源于氨基酸苯丙氨酸。越来越多的研究表明,PAGln 水平与不同心血管疾病的风险相关。在这篇综述中,我们讨论了 PAGln 产生的代谢途径和 PAGln 的定量测量方法。我们总结了流行病学证据,表明 PAGln 在心力衰竭、冠心病/动脉粥样硬化和心律失常等几种心血管疾病中的诊断和预后价值。目前认为 PAGln 的作用机制与血小板通过肾上腺素能受体的血栓形成潜力有关。此外,PAGln 还可能通过炎症反应和氧化应激等其他机制诱导。此外,由于 PAGln 是在包括肠道、肝脏和肾脏在内的不同器官中产生的,因此多个器官之间的相互作用集中在这种尿毒症毒性代谢物的功能上。最后,讨论了 PAGln 与经典生物标志物相比的预后价值,我们还强调了在心血管疾病中研究 PAGln 方面存在的重要知识空白和需要进一步研究的领域。

相似文献

1
Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease: current knowledge and new insights.肠道微生物依赖的苯乙酰谷氨酰胺与心血管疾病:现有知识和新见解。
Front Med. 2024 Feb;18(1):31-45. doi: 10.1007/s11684-024-1055-9. Epub 2024 Mar 1.
2
A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors.一种与心血管疾病相关的肠道微生物代谢物通过肾上腺素能受体发挥作用。
Cell. 2020 Mar 5;180(5):862-877.e22. doi: 10.1016/j.cell.2020.02.016.
3
Prognostic value of gut microbe-generated metabolite phenylacetylglutamine in patients with heart failure.肠道微生物衍生代谢产物苯乙酰谷氨酰胺对心力衰竭患者的预后价值。
Eur J Heart Fail. 2024 Feb;26(2):233-241. doi: 10.1002/ejhf.3111. Epub 2024 Jan 25.
4
Two distinct gut microbial pathways contribute to meta-organismal production of phenylacetylglutamine with links to cardiovascular disease.两种不同的肠道微生物途径共同导致苯乙酰谷氨酰胺的代谢产物生成,这与心血管疾病有关。
Cell Host Microbe. 2023 Jan 11;31(1):18-32.e9. doi: 10.1016/j.chom.2022.11.015. Epub 2022 Dec 21.
5
Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure.肠道微生物群衍生的苯乙酰谷氨酰胺与心力衰竭。
Circ Heart Fail. 2023 Jan;16(1):e009972. doi: 10.1161/CIRCHEARTFAILURE.122.009972. Epub 2022 Dec 16.
6
Role of the Gut Bacteria-Derived Metabolite Phenylacetylglutamine in Health and Diseases.肠道细菌衍生代谢物苯乙酰谷氨酰胺在健康与疾病中的作用
ACS Omega. 2024 Jan 8;9(3):3164-3172. doi: 10.1021/acsomega.3c08184. eCollection 2024 Jan 23.
7
Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure.苯乙酰谷氨酰胺作为心力衰竭的风险因素和预后指标。
ESC Heart Fail. 2022 Aug;9(4):2645-2653. doi: 10.1002/ehf2.13989. Epub 2022 May 27.
8
Dysbiosis of Gut Microbiota and Metabolite Phenylacetylglutamine in Coronary Artery Disease Patients With Stent Stenosis.冠状动脉支架狭窄患者肠道微生物群失调与代谢物苯乙酰谷氨酰胺的关系
Front Cardiovasc Med. 2022 Mar 25;9:832092. doi: 10.3389/fcvm.2022.832092. eCollection 2022.
9
Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis.血浆苯丙氨酸和肠道微生物群衍生代谢物苯乙酰谷氨酰胺在冠状动脉支架内再狭窄中的预后价值。
Front Cardiovasc Med. 2022 Aug 30;9:944155. doi: 10.3389/fcvm.2022.944155. eCollection 2022.
10
Gut microbe-generated phenylacetylglutamine is an endogenous allosteric modulator of β2-adrenergic receptors.肠道微生物产生的苯乙酰谷氨酰胺是β2-肾上腺素能受体的内源性别构调节剂。
Nat Commun. 2024 Aug 6;15(1):6696. doi: 10.1038/s41467-024-50855-3.

引用本文的文献

1
Association of Phenylacetylglutamine and Cognitive Impairment in CKD.慢性肾脏病中苯乙酰谷氨酰胺与认知障碍的关联
Kidney Int Rep. 2025 May 29;10(8):2720-2731. doi: 10.1016/j.ekir.2025.05.037. eCollection 2025 Aug.
2
Advancements in research to mitigate residual risk of atherosclerotic cardiovascular disease.减轻动脉粥样硬化性心血管疾病残余风险的研究进展。
Eur J Med Res. 2025 Aug 12;30(1):735. doi: 10.1186/s40001-025-03006-3.
3
Gut-derived uremic toxins and cardiovascular health in chronic kidney disease.慢性肾脏病中肠道源性尿毒症毒素与心血管健康

本文引用的文献

1
Comorbidities and heart failure: heterogeneity and challenges to fill in the gaps.合并症与心力衰竭:异质性及填补差距的挑战
Lancet Glob Health. 2023 Dec;11(12):e1830-e1831. doi: 10.1016/S2214-109X(23)00449-7.
2
Gut microbe-derived metabolite indole-3-carboxaldehyde alleviates atherosclerosis.肠道微生物衍生代谢产物吲哚 - 3 - 甲醛可减轻动脉粥样硬化。
Signal Transduct Target Ther. 2023 Oct 4;8(1):378. doi: 10.1038/s41392-023-01613-2.
3
Pea hull fiber supplementation does not modulate uremic metabolites in adults receiving hemodialysis: a randomized, double-blind, controlled trial.
Tzu Chi Med J. 2025 Apr 11;37(3):264-274. doi: 10.4103/tcmj.tcmj_293_24. eCollection 2025 Jul-Sep.
4
Threshold of phenylacetylglutamine changes: exponential growth between age and gut microbiota in stroke patients.苯乙酰谷氨酰胺变化阈值:中风患者年龄与肠道微生物群之间的指数增长关系
Front Neurol. 2025 May 21;16:1576777. doi: 10.3389/fneur.2025.1576777. eCollection 2025.
5
The Role of the Gut Microbiota in Heart Failure: Pathophysiological Insights and Future Perspectives.肠道微生物群在心力衰竭中的作用:病理生理学见解与未来展望
Medicina (Kaunas). 2025 Apr 14;61(4):720. doi: 10.3390/medicina61040720.
6
Indoleacetylglutamine Pathway Is a Potential Biomarker for Cardiovascular Diseases.吲哚乙酰谷氨酰胺途径是心血管疾病的一种潜在生物标志物。
Biomolecules. 2025 Mar 5;15(3):377. doi: 10.3390/biom15030377.
7
Potential of gut microbiota metabolites in treating COPD: network pharmacology and Mendelian randomization approaches.肠道微生物群代谢产物在治疗慢性阻塞性肺疾病中的潜力:网络药理学和孟德尔随机化方法
Front Microbiol. 2024 Nov 25;15:1416651. doi: 10.3389/fmicb.2024.1416651. eCollection 2024.
补充豌豆皮纤维对接受血液透析的成年人的尿毒症代谢产物无调节作用:一项随机、双盲、对照试验。
Front Nutr. 2023 Jun 30;10:1179295. doi: 10.3389/fnut.2023.1179295. eCollection 2023.
4
'Debugging' heart failure.“调试”心力衰竭
J Intern Med. 2023 Oct;294(4):374-376. doi: 10.1111/joim.13691. Epub 2023 Jul 9.
5
Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality.肠道微生物衍生芳香族氨基酸产物图谱与心血管疾病发病和死亡风险
Eur Heart J. 2023 Aug 22;44(32):3085-3096. doi: 10.1093/eurheartj/ehad333.
6
Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients.循环苯乙酰谷氨酰胺浓度升高可提高心力衰竭患者心血管事件风险的预测价值。
J Intern Med. 2023 Oct;294(4):515-530. doi: 10.1111/joim.13653. Epub 2023 May 30.
7
Profiling the human intestinal environment under physiological conditions.在生理条件下描绘人体肠道环境。
Nature. 2023 May;617(7961):581-591. doi: 10.1038/s41586-023-05989-7. Epub 2023 May 10.
8
Microbial metabolites in chronic heart failure and its common comorbidities.慢性心力衰竭及其常见合并症中的微生物代谢产物。
EMBO Mol Med. 2023 Jun 7;15(6):e16928. doi: 10.15252/emmm.202216928. Epub 2023 May 8.
9
Intestinal Lymphatic Dysfunction in Kidney Disease.肾脏疾病中的肠淋巴功能障碍。
Circ Res. 2023 Apr 28;132(9):1226-1245. doi: 10.1161/CIRCRESAHA.122.321671. Epub 2023 Apr 27.
10
Even or skewed dietary protein distribution is reflected in the whole-body protein net-balance in healthy older adults: A randomized controlled trial.均衡或不均衡的膳食蛋白质分布反映在健康老年人的全身蛋白质净平衡中:一项随机对照试验。
Clin Nutr. 2023 Jun;42(6):899-908. doi: 10.1016/j.clnu.2023.04.004. Epub 2023 Apr 8.